rapacuronium造句

• In a news release issued Thursday, the FDA said Organon was notified the five deaths happened during the administration of Raplon, the trade name for rapacuronium bromide.
• The drug, rapacuronium bromide, or Raplon, has been linked to roughly 90 fatal and nonfatal cases of bronchospasm, in which patients were unable to breathe normally.
• However, this particular undesirable effect does not appear to be observed nearly as often as that seen with rapacuronium, which led to the latter's withdrawal of approval for clinical use worldwide.
• Bronchospasm was not an unknown phenomenon prior to rapacuronium : occasional reports of bronchospasm have been noted also with the prototypical agents, tubocurarine and succinylcholine, as well as alcuronium, pancuronium, vecuronium, and gallamine.
• Recent data from studies in Guinea pigs confirm that gantacurium ( as well as cisatracurium ) is devoid of significant effects at airway muscarinic receptors and therefore, unlike rapacuronium ( Raplon ), not likely to cause bronchospasm at clinically relevant doses.
• That is not to say that bronchospasm was an unknown phenomenon prior to rapacuronium : occasional reports of bronchospasm have been noted also with the prototypical agents, tubocurarine and succinylcholine, as well as atracurium, alcuronium, pancuronium, vecuronium, and gallamine.
• The issue of bronchospasm acquired prominence in the neuromuscular-blocking agents arena after the withdrawal from clinical use of rapacuronium ( Raplon-a steroidal neuromuscular-blocking agent marketed by Organon ) in 2001 after several serious events of bronchospasm, including five unexplained fatalities, following its administration.
• "' Rapacuronium "'( "'Raplon "') is a rapidly acting, non-depolarizing neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care.
• The issue of bronchospasm acquired considerable prominence in the neuromuscular blocking agents arena after the spectacular failure of a clinically introduced neuromuscular blocking agent, rapacuronium ( Raplon a steroidal neuromuscular blocking agent marketed by Organon, now subsumed into Merck & Co . Inc . ), which had to be withdrawn voluntarily during the week of March 19, 2001 from clinical use ( < 2 years after its approval by the US FDA on August 18, 1999 NME Drug and New Biologic Approvals in 1999 ) after several serious events of bronchospasm, including five " unexplained " fatalities, following its administration.